Glioblastoma — clinical trials in Spain
15 open options
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debio 0123 · Temozolomide · Radiotherapy — 16 sites
- TRIALPHASE4RECRUITING
Dabrafenib and/or Trametinib Rollover Study
dabrafenib · trametinib — 33 sites
- TRIALPHASE2RECRUITING
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
DNX-2401 — 2 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Olaparib; 177Lu-DOTATATE — 1 site
- TRIALPHASE3RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Lomustine · Reirradiation — 45 sites
- TRIALNANOT_YET_RECRUITING
Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma
GlioHook device — 3 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE2RECRUITING
Surgery for Recurrent Glioblastoma
Surgery followed by adjuvant second-line therapy · Second-line therapy alone — 25 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Oral repotrectinib (TPX-0005) — 68 sites
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALPHASE1RECRUITING
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
hypofractionated stereotactic radiotherapy · Stereotactic biopsy · resection — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 60 sites
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Plixorafenib — 70 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.